<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501107</url>
  </required_header>
  <id_info>
    <org_study_id>CT037-ADO02</org_study_id>
    <nct_id>NCT04501107</nct_id>
  </id_info>
  <brief_title>A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomised, Double Blind, Crossover Euglycaemic Clamp Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, randomised, double-blind, 4-way crossover, 4-treatment, euglycaemic&#xD;
      clamp study in subjects with Type 1 Diabetes Mellitus (T1DM). Each subject will be randomly&#xD;
      allocated to one of four treatment sequences. Each sequence comprises one single dose of each&#xD;
      of four IMPs. IMP1 and IMP2 are BioChaperone lispro formulations. They have the same&#xD;
      composition and correspond to different development stages of a unique product which is&#xD;
      BioChaperone insulin lispro; between them, improvements were made to prepare industrial&#xD;
      production. Comparators (IMP3 and IMP4) are US-approved Humalog® and EU-approved Humalog®.&#xD;
      All IMPs will be dosed at 0.2 U/Kg of insulin lispro on 4 dosing visits separated by a&#xD;
      washout period of 5 to 15 days.&#xD;
&#xD;
      The trial will compare the characteristics of BioChaperone insulin lispro fully liquid (IMP2)&#xD;
      formulation to US-approved Humalog and EU-approved Humalog.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Actual">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">November 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCGIR.0-12h</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Area under the glucose infusion rate-time curve from time 0 until end of clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCGIR.0-1h</measure>
    <time_frame>From t=0 to t=1 hour after IMP administration</time_frame>
    <description>Area under the glucose infusion rate-time curve from time 0 to 1 hour after IMP administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCLIS.0-12h</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Area under the insulin lispro concentration-time curve from 0 hours to 12 hours after dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCLIS.0-1h</measure>
    <time_frame>From t=0 to t=1 hour after IMP administration</time_frame>
    <description>Area under the insulin lispro concentration-time curve from 0 hours to 1 hour after dose administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax.LIS</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Time to maximum observed insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax.LIS</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Maximum observed insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCLIS.2-6h</measure>
    <time_frame>From t=2 to t=6hours after IMP administration</time_frame>
    <description>Area under the insulin lispro concentration-time curve from 2 hour to 6 hour after dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t50%-LIS (early)</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Time to half-maximum before Cmax.LIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax.GIR</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax</measure>
    <time_frame>From t=0 to t=12 hours after IMP administration</time_frame>
    <description>Maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR.4-8h</measure>
    <time_frame>From t=4 to t=8 hours after IMP administration</time_frame>
    <description>Area under the glucose infusion rate-time curve from 4 to 8 hours after dose administration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro reconstituted with Humalog® (IMP1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of Biochaperone insulin lispro formulation made from a freeze-dried of BioChaperone reconstituted with Humalog® at a dose of 0.2 U/Kg Body Weight (BW).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ready-to-use BioChaperone insulin lispro (IMP2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of ready-to-use Biochaperone insulin lispro formulation at a dose of 0.2 U/Kg BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-approved Humalog® (IMP3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous administration of US-approved Humalog® at a dose of 0.2 U/Kg BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-approved Humalog® (IMP4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous administration of EU-approved Humalog® at a dose of 0.2 U/Kg BW.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)</intervention_name>
    <description>Administration of IMP1 during a 12-hour euglycaemic clamp.</description>
    <arm_group_label>BioChaperone insulin lispro reconstituted with Humalog® (IMP1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Ready-to-use BioChaperone insulin lispro (IMP2)</intervention_name>
    <description>Administration of IMP2 during a 12-hour euglycaemic clamp.</description>
    <arm_group_label>Ready-to-use BioChaperone insulin lispro (IMP2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of US-approved Humalog® (IMP3)</intervention_name>
    <description>Administration of IMP3 during a 12-hour euglycaemic clamp.</description>
    <arm_group_label>US-approved Humalog® (IMP3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of EU-approved Humalog® (IMP4)</intervention_name>
    <description>Administration of IMP4 during a 12-hour euglycaemic clamp.</description>
    <arm_group_label>EU-approved Humalog® (IMP4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with type 1 Diabetes Mellitus&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 and 28.5 kg/m^2, both inclusive&#xD;
&#xD;
          -  HbA1c &lt;= 75 mmol/mol (&lt;=9.0%).&#xD;
&#xD;
          -  Fasting negative C-peptide (&lt;= 0.30 nmol/L).&#xD;
&#xD;
          -  Total insulin dose of &lt; 1.2 (I)U/kg/day.&#xD;
&#xD;
          -  Stable insulin regimen (with respect to safety of the subject and scientific integrity&#xD;
             of the study) using continuous subcutaneous insulin infusion (CSII) or multiple daily&#xD;
             insulin injections (MDI) for at least 2 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to IMP(s) or related products.&#xD;
&#xD;
          -  Receipt of any medicinal product in clinical development within 30 days or at least 5&#xD;
             half-lives of the related substances and their metabolites (whichever is longer)&#xD;
             before randomisation in this trial.&#xD;
&#xD;
          -  History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction.&#xD;
&#xD;
          -  Any history or presence of cancer except basal cell skin cancer or squamous cell skin&#xD;
             cancer as judged by the Investigator.&#xD;
&#xD;
          -  Any history or presence of clinically relevant comorbidity capable of constituting a&#xD;
             risk for the subject when participating in the trial or of interfering with the&#xD;
             interpretation of data.&#xD;
&#xD;
          -  Signs of acute illness as judged by the Investigator.&#xD;
&#xD;
          -  Any serious systemic infectious disease during four weeks prior to first dosing of the&#xD;
             trial drug, as judged by the Investigator.&#xD;
&#xD;
          -  Clinically significant abnormal screening laboratory tests, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Proliferative retinopathy or maculopathy as judged by the Investigator based on a&#xD;
             recent (&lt;1.5 years) ophthalmologic examination.&#xD;
&#xD;
          -  Use of oral antidiabetic drugs (OADs) and/or GLP-1 receptor agonists within 3 months&#xD;
             prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugen Baumgaertner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil GmbH</name>
      <address>
        <city>Mainz</city>
        <zip>D-55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

